Cargando…

Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment

OBJECTIVE: In observational data, lower levels of lipoprotein(a) have been associated with greater prevalence of type 2 diabetes. Whether pharmacologic lowering of lipoprotein(a) influences incident type 2 diabetes is unknown. We determined the relationship of lipoprotein(a) concentration with incid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwartz, Gregory G., Szarek, Michael, Bittner, Vera A., Bhatt, Deepak L., Diaz, Rafael, Goodman, Shaun G., Jukema, J. Wouter, Loy, Megan, Manvelian, Garen, Pordy, Robert, White, Harvey D., Steg, Philippe Gabriel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2021
Materias:	Cardiovascular and Metabolic Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132323/ https://www.ncbi.nlm.nih.gov/pubmed/33722880 http://dx.doi.org/10.2337/dc20-2842

Ejemplares similares

Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Correction: Effect of alirocumab on cataracts in patients with acute coronary syndromes
por: Suc, Gaspard, et al.
Publicado: (2023)

Clinical Efficacy and Safety of Alirocumab After Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score–Matched Analysis of the ODYSSEY OUTCOMES Trial
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial
por: Schwartz, Gregory G, et al.
Publicado: (2023)

Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
por: Schwartz, Gregory G., et al.
Publicado: (2020)

Long‐Term Efficacy, Safety, and Tolerability of Alirocumab in 8242 Patients Eligible for 3 to 5 Years of Placebo‐Controlled Observation in the ODYSSEY OUTCOMES Trial
por: Goodman, Shaun G., et al.
Publicado: (2023)

Alirocumab after acute coronary syndrome in patients with a history of heart failure
por: White, Harvey D, et al.
Publicado: (2021)

Effect of Alirocumab on Stroke in ODYSSEY OUTCOMES
por: Jukema, J. Wouter, et al.
Publicado: (2019)

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
por: Schwartz, Gregory G., et al.
Publicado: (2021)

Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
por: Szarek, Michael, et al.
Publicado: (2020)

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials
por: Mohammadi, Kusha A., et al.
Publicado: (2023)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial
por: Tuñón, José, et al.
Publicado: (2020)

Effect of alirocumab on cardiovascular outcomes after acute coronary syndromes according to age: an ODYSSEY OUTCOMES trial analysis
por: Sinnaeve, Peter R, et al.
Publicado: (2020)

Effect of Alirocumab on Mortality After Acute Coronary Syndromes: An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial
por: Steg, Philippe Gabriel, et al.
Publicado: (2019)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Ethnic differences in serum lipids and lipoproteins in overweight/obese African-American and white American women with pre-diabetes: significance of NMR-derived lipoprotein particle concentrations and sizes
por: Gaillard, Trudy, et al.
Publicado: (2016)

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes
por: Roe, Matthew T., et al.
Publicado: (2019)

Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial
por: Moriarty, Patrick M., et al.
Publicado: (2016)

A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes
por: Berg, David D., et al.
Publicado: (2021)

Sex Differences in Diabetes Risk and the Effect of Intensive Lifestyle Modification in the Diabetes Prevention Program
por: Perreault, Leigh, et al.
Publicado: (2008)

Pharmacogenomic Study of Statin-Associated Muscle Symptoms in the ODYSSEY OUTCOMES Trial
por: Murphy, William A., et al.
Publicado: (2022)

Treatment adherence and effect of concurrent statin intensity on the efficacy and safety of alirocumab in a real-life setting: results from ODYSSEY APPRISE
por: Banach, Maciej, et al.
Publicado: (2021)

Risk of Glucose Intolerance and Diabetes in Hemipancreatectomized Donors Selected for Normal Preoperative Glucose Metabolism
por: Kumar, Anjali F., et al.
Publicado: (2008)

Increased Daily Walking Improves Lipid Oxidation Without Changes in Mitochondrial Function in Type 2 Diabetes
por: Trenell, Michael I., et al.
Publicado: (2008)

Uncovering heterogeneous cardiometabolic risk profiles in US adults: the role of social and behavioral determinants of health
por: Ding, Qinglan, et al.
Publicado: (2023)

Is Socioeconomic Position Related to the Prevalence of Metabolic Syndrome?: Influence of social class across the life course in a population-based study of older men
por: Ramsay, Sheena E., et al.
Publicado: (2008)

Effect of high-salt diet on blood pressure and body fluid composition in patients with type 1 diabetes: randomized controlled intervention trial
por: Wenstedt, Eliane F E, et al.
Publicado: (2020)

Global Coronary Heart Disease Risk Assessment of Individuals With the Metabolic Syndrome in the U.S.
por: Hoang, Khiet C., et al.
Publicado: (2008)

Egg ingestion in adults with type 2 diabetes: effects on glycemic control, anthropometry, and diet quality—a randomized, controlled, crossover trial
por: Njike, Valentine Y, et al.
Publicado: (2016)

Glucose Intolerance in Pregnancy and Future Risk of Pre-Diabetes or Diabetes
por: Retnakaran, Ravi, et al.
Publicado: (2008)

All-Cause and Specific-Cause Mortality Risk After Roux-en-Y Gastric Bypass in Patients With and Without Diabetes
por: Lent, Michelle R., et al.
Publicado: (2017)

Inclusion of walnut in the diets of adults at risk for type 2 diabetes and their dietary pattern changes: a randomized, controlled, cross-over trial
por: Njike, Valentine Yanchou, et al.
Publicado: (2016)

Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study
por: Posch, Maximilian G., et al.
Publicado: (2022)

Lipid-lowering treatment patterns among patients with type 2 diabetes mellitus with high cardiovascular disease risk
por: Quek, Ruben G W, et al.
Publicado: (2015)

Fitness, Fatness, and Survival in Adults With Prediabetes
por: McAuley, Paul A., et al.
Publicado: (2014)

Association Between Metabolic Syndrome and Depressive Symptoms in Middle-Aged Adults: Results from the Whitehall II study
por: Akbaraly, Tasnime N., et al.
Publicado: (2009)

Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S.
por: Basu, Sanjay, et al.
Publicado: (2018)

Heart Rate and Heart Rate Variability Changes Are Not Related to Future Cardiovascular Disease and Death in People With and Without Dysglycemia: A Downfall of Risk Markers? The Whitehall II Cohort Study
por: Hansen, Christian S., et al.
Publicado: (2021)

Evaluating the prognostic performance of bedside tests used for peripheral arterial disease diagnosis in the prediction of diabetic foot ulcer healing
por: Elghazaly, Hussein, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6nla0gtdr73lbr39k3ves1s4dn